000518.SZ Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (25 Apr 2024 @ 00:09):

Stats
Today's Volume	8.81M
Average Volume	34.76M
Market Cap	2.19B
EPS	CNY-0.0183 ( 2023-06-30 )
Last Dividend	CNY0 ( N/A )
Next Dividend	CNY0 ( N/A )
P/E	-35.50
ATR14	CNY0.00700 (0.33%)

Volume Correlation

Long: -0.03 (neutral)

Short: -0.41 (neutral)

Signal:(45.527) Neutral

Jiangsu Sihuan Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Jiangsu Sihuan Correlation - Currency/Commodity

0.73
( moderate )

0.00
( neutral )

0.31
( neutral )

Jiangsu Sihuan Financials

Annual	2022
Revenue:	CNY270.15M
Gross Profit:	CNY191.90M (71.03 %)
EPS:	CNY-0.0518

Q3	2023
Revenue:	CNY58.52M
Gross Profit:	CNY41.31M (70.58 %)
EPS:	CNY-0.00540

Q2	2023
Revenue:	CNY64.40M
Gross Profit:	CNY47.49M (73.74 %)
EPS:	CNY-0.0183

Q1	2023
Revenue:	CNY57.01M
Gross Profit:	CNY38.94M (68.30 %)
EPS:	CNY-0.0205

Financial Reports:

No articles found.

Jiangsu Sihuan

Jiangsu Sihuan Bioengineering Co., Ltd. engages in the pharmaceutical business in China. It offers Drewson, an anti-tumor biotherapeutic drug for the treatment of renal cancer, malignant melanoma, and cancerous thoracic and peritoneal effusion; and Xinde Lusheng for the treatment of kidney cancer, melanoma, lung cancer, gastric cancer, malignant lymphoma, breast cancer, ovarian tumor, bowel cancer, bladder cancer, head and neck tumor, leukemia and cancerous pleural effusion, etc. The company also provides Xin grain health, a recombinant human granulocyte colony stimulating factor injection; and Tourbo, a recombinant human erythropoietin injection for the treatment of anemia caused by renal insufficiency, including dialysis and non-dialysis patients. Jiangsu Sihuan Bioengineering Co., Ltd. was founded in 1992 and is headquartered in Jiangyin, China.